Anavex (AVXL) interim CEO discloses detailed stock option grants

Rhea-AI Filing Summary

ANAVEX LIFE SCIENCES CORP. Interim CEO Terrie Kellmeyer has filed an initial Form 3 showing holdings of stock options rather than recent trades. The filing lists three option grants over common stock: options covering 50,000 shares with an exercise price of $8.58 expiring on March 31, 2035; 7,500 shares at $5.36 expiring on February 20, 2034; and 46,668 shares at $7.21 expiring on November 30, 2033, all held directly.

Footnotes clarify vesting: the 50,000-share grant includes 35,001 fully vested options and 11,667 that vest in two substantially equal tranches on June 30, 2026 and September 30, 2026. The 7,500-share grant includes 2,500 fully vested options and 5,000 that vest in two equal tranches based on performance milestones. Another 50,000-share grant includes 25,000 fully vested options and 25,000 that will vest in two equal performance-based tranches.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Kellmeyer Terrie

Role Interim CEO

Type	Security	Shares	Price	Value
holding	Options (Right to Buy)	--	--	--
holding	Options (Right to Buy)	--	--	--
holding	Options (Right to Buy)	--	--	--

Holdings After Transaction: Options (Right to Buy) — 46,668 shares (Direct, null)

Footnotes (1)

1. Includes 35,001 fully vested options and 11,667 unvested options that will vest in two substantially equal tranches on June 30, 2026 and September 30, 2026. Includes 2,500 fully vested options and 5,000 options which will vest in two equal tranches based on two performance milestones. Includes 25,000 fully vested options and 25,000 options which will vest in two equal tranches based on two performance milestones.

Key Figures

Options at $8.58: 50,000 underlying shares Options at $5.36: 7,500 underlying shares Options at $7.21: 46,668 underlying shares +4 more

7 metrics

Options at $8.58 50,000 underlying shares Exercise price $8.58, expiration March 31, 2035, direct holding

Options at $5.36 7,500 underlying shares Exercise price $5.36, expiration February 20, 2034, direct holding

Options at $7.21 46,668 underlying shares Exercise price $7.21, expiration November 30, 2033, direct holding

Fully vested within 50,000 grant 35,001 options Part of 50,000-share grant at $8.58

Time-based vesting in 50,000 grant 11,667 options Vest in two tranches on June 30, 2026 and September 30, 2026

Performance-based vesting in 7,500 grant 5,000 options Vest in two equal tranches based on performance milestones

Performance-based vesting in 50,000 grant 25,000 options Vest in two equal tranches based on performance milestones

Key Terms

Interim CEO, fully vested options, performance milestones

3 terms

Interim CEO financial

"Kellmeyer Terrie, Interim CEO"

An interim CEO is a temporary chief executive appointed to lead a company for a short, defined period while the board searches for a permanent leader or handles an unexpected vacancy. Investors watch this role because the interim's decisions and tone can affect day-to-day operations, strategic direction, and market confidence—like a substitute teacher keeping a classroom running until a full-time teacher arrives, the interim can stabilize or shift momentum and influence the stock's outlook.

fully vested options financial

"Includes 35,001 fully vested options and 11,667 unvested options"

performance milestones financial

"5,000 options which will vest in two equal tranches based on two performance milestones"

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kellmeyer Terrie

(Last) (First) (Middle)

630 5TH AVENUE

20TH FLOOR

(Street)

NEW YORK NEW YORK 10111

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/04/2026

3. Issuer Name and Ticker or Trading Symbol
ANAVEX LIFE SCIENCES CORP. [ AVXL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CEO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	(1)	11/30/2033	Common Stock	46,668	$7.21	D
Options (Right to Buy)	(2)	02/20/2034	Common Stock	7,500	$5.36	D
Options (Right to Buy)	(3)	03/31/2035	Common Stock	50,000	$8.58	D

Explanation of Responses:

1. Includes 35,001 fully vested options and 11,667 unvested options that will vest in two substantially equal tranches on June 30, 2026 and September 30, 2026.

2. Includes 2,500 fully vested options and 5,000 options which will vest in two equal tranches based on two performance milestones.

3. Includes 25,000 fully vested options and 25,000 options which will vest in two equal tranches based on two performance milestones.

	/s/ Terrie Kellmeyer	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the ANAVEX (AVXL) Form 3 for Terrie Kellmeyer report?

The Form 3 reports Terrie Kellmeyer’s existing stock option holdings as Interim CEO. It lists three option grants over ANAVEX common stock, detailing exercise prices, expiration dates, and how many options are already vested versus scheduled to vest over time.

How many ANAVEX (AVXL) options does the interim CEO hold and at what prices?

The filing shows options over 50,000 shares at $8.58, 7,500 shares at $5.36, and 46,668 shares at $7.21. All are options on ANAVEX common stock, held directly, with long-dated expiration schedules extending into 2033–2035.

What are the vesting terms of Terrie Kellmeyer’s 50,000 ANAVEX options at $8.58?

Of this 50,000-share grant, 35,001 options are fully vested and 11,667 are unvested. The unvested portion is scheduled to vest in two substantially equal tranches on June 30, 2026 and September 30, 2026, subject to continued conditions.

How are performance milestones used in ANAVEX (AVXL) interim CEO option vesting?

Two of the option grants vest partly based on performance milestones. A 7,500-share grant includes 5,000 options vesting in two equal performance-based tranches, and another 50,000-share grant includes 25,000 options vesting in two equal tranches tied to performance targets.

Does the ANAVEX (AVXL) Form 3 show recent insider buying or selling by the interim CEO?

No recent purchases or sales are indicated; the entries are holdings of existing options. The Form 3 simply establishes Terrie Kellmeyer’s beneficial ownership position in ANAVEX stock options upon becoming a reportable insider.